Norgine Advances Treatment for WHIM Syndrome with Positive CHMP Recommendation for mavorixafor

Norgine’s Milestone in Rare Disease Treatment: A Step Forward for WHIM Syndrome Patients

Norgine B.V., a notable European specialty pharmaceutical company, advances its commitment to addressing rare diseases with the recent positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding XOLREMDI® (mavorixafor). This pivotal drug is designed to treat WHIM syndrome, a debilitating ultra-rare disorder characterized by warts, hypogammaglobulinemia, recurrent infections, and myelokathexis. The condition arises from a malfunction of the CXCR4 chemokine receptor, which plays a crucial role in mobilizing white blood cells from the bone marrow. Currently, patients with WHIM syndrome lack licensed treatments, making this recommendation a significant milestone for both Norgine and the patients awaiting therapeutic options.

The positive CHMP opinion is based on results from the phase 3 clinical trial (4WHIM), a rigorous global study that involved 31 patients aged 12 and older. The trial employed a randomized, double-blind, placebo-controlled design to assess the safety and efficacy of mavorixafor. With the European Commission expected to render its final decision in the second quarter of 2026, Norgine is keenly positioned to spearhead market access and commercialization efforts should the drug receive regulatory approval. According to Janneke van der Kamp, Norgine's CEO, the recommendation represents a robust step towards delivering much-needed innovative treatments and underscores the company's dedication to addressing rare diseases across Europe, Australia, and New Zealand.

Further reinforcing Norgine’s strategic approach in this area, the company recently established a licensing and supply agreement with X4 Pharmaceuticals. This partnership, initiated in January 2025, lays the groundwork for Norgine to manage the commercialization of mavorixafor in the aforementioned regions post-approval. X4 will retain manufacturing and supply duties for the drug, allowing Norgine to focus on its strengths in market access. This collaboration not only enhances Norgine’s capabilities as a specialty pharmaceutical operator but also exemplifies its commitment to transforming innovative research into accessible treatments for highly specialized medical needs.

In addition to its efforts with WHIM syndrome, Norgine’s focus reflects a growing trend within the pharmaceutical industry toward addressing ultra-rare conditions that have traditionally been neglected. As more companies like Norgine expand their portfolios into the realm of rare diseases, patients with complex medical needs stand to benefit from emerging therapeutic advancements, ultimately fostering greater accessibility to effective treatments.